Published in Oncotarget on May 24, 2016
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (1999) 34.47
Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol (2004) 17.54
Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol (2003) 15.51
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol (2002) 9.45
Distinction of virgin and memory T lymphocytes. Stable acquisition of the Pgp-1 glycoprotein concomitant with antigenic stimulation. J Immunol (1987) 5.07
Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci U S A (2004) 4.93
Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med (2005) 4.45
Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 3.95
CD27 is required for generation and long-term maintenance of T cell immunity. Nat Immunol (2000) 3.84
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature (2005) 3.81
Activation phenotype, rather than central- or effector-memory phenotype, predicts the recall efficacy of memory CD8+ T cells. J Exp Med (2007) 3.09
New horizons in adjuvants for vaccine development. Trends Immunol (2008) 2.85
The known unknowns of antigen processing and presentation. Nat Rev Immunol (2008) 2.85
Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. J Immunol (2005) 2.80
Jump-starting the immune system: prime-boosting comes of age. Trends Immunol (2004) 2.61
Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation. Immunity (2010) 2.38
Effector-like CD8⁺ T cells in the memory population mediate potent protective immunity. Immunity (2013) 2.30
Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29
A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol (2003) 2.04
Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol (2005) 2.01
T-cell memory and recall responses to respiratory virus infections. Immunol Rev (2006) 1.95
CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med (2004) 1.92
Cutting edge: effector memory CD8+ T cells play a prominent role in recall responses to secondary viral infection in the lung. J Immunol (2004) 1.90
Cytotoxic T cells. J Invest Dermatol (2006) 1.47
Lipopeptide vaccines--yesterday, today, and tomorrow. Lancet Infect Dis (2002) 1.41
The effects of TLR activation on T-cell development and differentiation. Clin Dev Immunol (2012) 1.33
Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A (2013) 1.20
Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res (2012) 1.15
Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol (2012) 1.14
Self-adjuvanting lipopeptide vaccines. Curr Med Chem (2008) 1.10
Development of antigen cross-presentation capacity in dendritic cells. Trends Immunol (2012) 1.08
Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther (2004) 1.08
Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J Immunol (2000) 1.05
TLR3 ligand stimulates fully functional memory CD8+ T cells in the absence of CD4+ T-cell help. Blood (2007) 1.04
A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine (2009) 0.98
The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J Immunol (2010) 0.97
Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J Immunol (2011) 0.95
CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8α+ dendritic cells [corrected]. J Immunol (2010) 0.95
A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol Immunol (2010) 0.94
TLR and nucleotide-binding oligomerization domain-like receptor signals differentially regulate exogenous antigen presentation. J Immunol (2011) 0.93
Understanding the biology of antigen cross-presentation for the design of vaccines against cancer. Front Immunol (2014) 0.93
Recombinant lipidated HPV E7 induces a Th-1-biased immune response and protective immunity against cervical cancer in a mouse model. PLoS One (2012) 0.92
TLR4 ligands lipopolysaccharide and monophosphoryl lipid a differentially regulate effector and memory CD8+ T Cell differentiation. J Immunol (2014) 0.91
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8(+) T-cell responses to anticancer vaccines. Oncoimmunology (2013) 0.88
Rapid isolation and characterization of bacterial lipopeptides using liquid chromatography and mass spectrometry analysis. Proteomics (2011) 0.87
Nanoparticle adjuvant sensing by TLR7 enhances CD8+ T cell-mediated protection from Listeria monocytogenes infection. J Immunol (2013) 0.87
A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity. J Control Release (2013) 0.87
A novel single-dose dengue subunit vaccine induces memory immune responses. PLoS One (2011) 0.85
The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses. Immunol Cell Biol (2014) 0.83
Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. Arch Immunol Ther Exp (Warsz) (2009) 0.82
Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells. J Immunol (2014) 0.80
A purified recombinant lipopeptide as adjuvant for cancer immunotherapy. Biomed Res Int (2014) 0.77